Exagen Diagnostics(TM), Inc. Announces an Oral Presentation of a Clinical Study on Genomic Biomarkers for Breast Cancer at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
Posted on: Tuesday, 29 May 2007, 18:00 CDT
Exagen Diagnostics, Inc. announces that it will offer an oral presentation from a multi-site clinical study of genomic markers for breast cancer on Saturday, June 2nd.
ABSTRACT TITLE: "Validation of genomic markers that predict distant recurrence risk via FISH assays in women with early stage breast cancer"
PRESENTED AT ASCO BY:
Collaborative presentation by Tom Williams, MD, Chief Scientific Officer at Exagen Diagnostics, and other authors of the clinical study
TIME/PLACE:
Saturday, June 2, 2007, 9:00 a.m.
2007 ASCO Annual Meeting
Room E450b
McCormick Place
Chicago, Illinois
CONTACTS:
212-233-2212
HarrisonCecil Communications
Mary Ellen Bos, ext 3631 mebos@HarrisonCecil.com
James Cecil, ext 3630 jcecil@HarrisonCecil.com
About Exagen Diagnostics, Inc.
An emerging leader in the development of genomic biomarker IVD kits, Exagen is uniquely able to discover, validate and deliver products based on small sets of genomic markers for use in the fields of cancer, gastroenterology, infectious disease and general medicine. The company's first test, currently under review by the FDA, predicts the risk of breast cancer recurrence by offering greater information to patients and healthcare providers. www.exagen.com
Source: Business Wire
Related Articles
- Breast Cancer's Genetic Marker: Mutation Associated With Jewish Women
- NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
- Power3's Dr. Ira Goldknopf to Present Results on Breast Cancer and Alzheimer's to Cancer Proteomics and Molecular Diagnostics World Congresses in Philadelphia
- NYU Medical Center Partners With Rosetta Genomics to Develop a Line of Diagnostic Tools for Lung and Mesothelioma Cancers
- Breast Cancer Subtype Markers Found
- St. Louis Cancer & Breast Institute Physician Says Hormone Replacement Therapy Does Indeed Create Breast Cancer Risk
- Illumina Awarded Genotyping Contract By SAIC-Frederick, Inc. For Cancer Genetics Marker Susceptibility (CGEMS) Study
- Genesis Bioventures Announces Breast Cancer Marker Receives Diagnostic and Therapeutic Patent Approval
- HEALTH: 10 FACTS YOU SHOULD KNOW ABOUT BEATING BREAST CANCER ; Breast Cancer is Estimated to Affect One in Nine Women in Britain. Luckily, There Have Been Huge Developments in Treatments Available Heres a Look at What the Future Holds for the Fight Again
- MR Spectroscopy Helps Identify Cancerous Breast Tumors
 |
 |
User Comments (0)
RSS Feeds